CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
oral delivery mucosal staindevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01520324
NCT01520324Phase 2Completed
CompareCT.gov

Intraepithelial Neoplasia Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Patients With Long Standing Ulcerative Colitis Undergoing Colonoscopy.

Cosmo Technologies Ltd·interventional·Posted Jan 27, 2012·Updated Feb 8, 2019

In Brief

A Phase 2 clinical trial evaluating oral delivery mucosal stain for Ulcerative Colitis. Completed, enrolled 53 participants across 1 site.

Detailed Summary

Evaluation of the intraepithelial neoplasia detection rate in patients with long standing ulcerative colitis undergoing mucosal staining with oral methylene blue MMX tablets prior to colonoscopy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 27, 2012
Enrollment StartJan 1, 2012
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.4 years ago

Interventions

oral delivery mucosal staindevice

200mg methylene blue MMX tablet taken prior to colonoscopy